Skip to main content
. Author manuscript; available in PMC: 2019 Sep 5.
Published in final edited form as: Vaccine. 2013 Jun 29;31(37):3899–3905. doi: 10.1016/j.vaccine.2013.06.050

Fig. 3.

Fig. 3.

The estimated decline in cervical intraepithelial neoplasia (CIN) 2/3 among females aged 20–29 years following onset of a quadrivalent HPV vaccination program under 6 vaccination scenarios. Two vaccination strategies (“Female-only vaccination” shown with solid lines and “Male and female vaccination” shown with dashed lines) for ages 12–26 years were modeled under three coverage levels (lower, intermediate, and higher) as described in Table 1.